Sou Hu Cai Jing·2026-01-30 07:00Group 1 - The pharmaceutical sector experienced a pullback, with the pharmaceutical ETF (159929) declining by 1.53% and a trading volume exceeding 1.3 billion yuan, indicating a net inflow of over 45 million yuan during the day, marking 11 consecutive days of capital inflow totaling over 360 million yuan [1][3] - Major stocks within the pharmaceutical ETF saw most decline, including Meien Health and Pianzaihuang dropping over 3%, WuXi AppTec and Aier Eye Hospital falling over 2%, while Tigermed rose over 7% [3][4] - Tigermed is projected to see a net profit growth of 105% to 204% by 2025, indicating strong future performance [3] Group 2 - The JPM 2026 conference highlighted a shift in the global pharmaceutical industry's focus towards the effective allocation and long-term value realization of innovations amidst rising uncertainties [5] - Chinese innovation is gaining global recognition, with increased participation from Chinese companies at the JPM 2026, reflecting a growing acknowledgment from international capital and multinational pharmaceutical companies [5][6] - The evaluation logic of multinational pharmaceutical companies regarding Chinese innovative assets is evolving, focusing on their efficacy, differentiation, and competitive positioning for inclusion in global product portfolios [6][10] Group 3 - Multinational pharmaceutical companies are entering a critical patent cliff period, necessitating diversification in their pipelines to mitigate risks associated with single products and treatment areas [10][12] - The integration of AI into core strategies is becoming mainstream, with AI being utilized to enhance R&D efficiency and optimize operational systems, thus addressing challenges posed by the patent cliff [12][13] - The oncology sector remains a core area for pharmaceutical innovation, with a focus on antibody-drug conjugates (ADCs) and cell therapies, indicating a robust pipeline and commercial potential [13][15]